Effects of Lidocaine-Derived Organic Compounds on Eosinophil Activation and Survival

• Published in: Molecules (Basel, Switzerland) Vol. 28; no. 15; p. 5696
• Main Authors: Shin, Seung-Heon, Ye, Mi-Kyung, Chae, Mi-Hyun, Geum, Sang-Yen, Aboraia, Ahmed S, Abdel-Aal, Abu-Baker M, Qayed, Wesam S, Abd El-Wahab, Hend A A, Abou-Ghadir, Ola F, Aboul-Fadl, Tarek
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.07.2023; MDPI
• Subjects: Analysis; anti-inflammation; Asthma; Cytokines; Design; Enzyme-linked immunosorbent assay; Enzymes; Hydrogen bonds; Inflammation; Lidocaine; lidocaine analog; ligand-based drug; pharmacophore; Superoxide; Transcription factors; anti-inflammation; lidocaine analog; pharmacophore; ligand-based drug
• DOI: 10.3390/molecules28155696
• ISSN: 1420-3049

Lidocaine, a local anesthetic, is known to possess anti-inflammatory properties. However, its clinical use is limited by inconveniences, such as its local synesthetic effects. This study evaluated lidocaine analogs designed and synthesized to overcome the disadvantages of lidocaine, having anti-inflammatory properties. Interleukin 5 (IL-5)-induced eosinophil activation and survival were evaluated using 36 lidocaine analogs with modified lidocaine structure on the aromatic or the acyl moiety or both. Eosinophil survival was evaluated using a CellTiter 96 aqueous cell proliferation assay kit. Superoxide production was determined using the superoxide dismutase-inhibitable reduction of cytochrome C method. Eosinophil cationic protein (ECP), IL-8, and transcription factor expression were determined using enzyme-linked immunosorbent assay. The platelet-activating factor (PAF)-induced migration assay was performed using a Transwell insert system. Compounds EI137 and EI341 inhibited IL-5-induced eosinophil survival and superoxide and ECP production in a concentration-dependent manner. These compounds also significantly reduced IL-8 production. Although compounds EI137 and EI341 significantly reduced phosphorylated ERK 1/2 expression, they did not influence other total and phosphorylated transcription factors. Moreover, 1000 µM of compound EI341 only inhibited PAF-induced migration of eosinophils. Lidocaine analogs EI137 and EI341 inhibited IL-5-mediated activation and survival of eosinophils. These compounds could be new therapeutic agents to treat eosinophilic inflammatory diseases.